Citadel Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-22,500
| Closed | -$405K | – | 11176 |
|
|
2020
Q2 | $405K | Sell |
22,500
-21,800
| -49% | -$303K | ﹤0.01% | 7435 |
|
|
2020
Q1 | $316K | Sell |
44,300
-49,000
| -53% | -$611K | ﹤0.01% | 7248 |
|
|
2019
Q4 | $2.23M | Sell |
93,300
-19,500
| -17% | -$538K | ﹤0.01% | 4239 |
|
|
2019
Q3 | $3.02M | Sell |
112,800
-136,900
| -55% | -$3.84M | ﹤0.01% | 3828 |
|
|
2019
Q2 | $6.77M | Buy |
249,700
+176,500
| +241% | +$5.53M | ﹤0.01% | 2679 |
|
|
2019
Q1 | $2.54M | Sell |
73,200
-12,400
| -14% | -$358K | ﹤0.01% | 4062 |
|
|
2018
Q4 | $1.67M | Buy |
85,600
+52,300
| +157% | +$1.08M | ﹤0.01% | 4431 |
|
|
2018
Q3 | $887K | Buy |
33,300
+10,800
| +48% | +$353K | ﹤0.01% | 5759 |
|
|
2018
Q2 | $850K | Sell |
22,500
-28,700
| -56% | -$1.1M | ﹤0.01% | 5499 |
|
|
2018
Q1 | $1.67M | Buy |
51,200
+15,000
| +41% | +$658K | ﹤0.01% | 4006 |
|
|
2017
Q4 | $1.76M | Buy |
36,200
+3,700
| +11% | +$187K | ﹤0.01% | 3812 |
|
|
2017
Q3 | $1.76M | Buy |
32,500
+8,000
| +33% | +$470K | ﹤0.01% | 3556 |
|
|
2017
Q2 | $1.38M | Buy |
24,500
+7,500
| +44% | +$300K | ﹤0.01% | 3651 |
|
|
2017
Q1 | $666K | Sell |
17,000
-5,100
| -23% | -$162K | ﹤0.01% | 4582 |
|
|
2016
Q4 | $496K | Buy |
22,100
+200
| +0.9% | +$3.91K | ﹤0.01% | 4907 |
|
|
2016
Q3 | $497K | Buy |
21,900
+10,800
| +97% | +$254K | ﹤0.01% | 4867 |
|
|
2016
Q2 | $262K | Sell |
11,100
-17,200
| -61% | -$425K | ﹤0.01% | 5427 |
|
|
2016
Q1 | $577K | Buy |
28,300
+19,500
| +222% | +$619K | ﹤0.01% | 4209 |
|
|
2015
Q4 | $453K | Sell |
8,800
-500
| -5% | -$24.2K | ﹤0.01% | 4594 |
|
|
2015
Q3 | $396K | Buy |
9,300
+2,600
| +39% | +$125K | ﹤0.01% | 5141 |
|
|
2015
Q2 | $305K | Buy |
6,700
+5,100
| +319% | +$205K | ﹤0.01% | 5718 |
|
|
2015
Q1 | $61K | Buy |
+1,600
| New | +$55K | ﹤0.01% | 7255 |
|
Citadel Advisors's PTLA Position: Q3 2020 in Review
Citadel Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 68,854 shares — an estimated $1.24M sold.
Citadel Advisors first reported a position in PTLA in Q1 2014 and held it in 26 quarters. The position peaked at $58.9M in Q4 2015. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Citadel Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Citadel Advisors sold 68,854 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $1.24M.
- Citadel Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q1 2014 and held it in 26 quarters.
- Citadel Advisors's Portola Pharmaceuticals, Inc. position peaked at $58.9M in Q4 2015.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Citadel Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.